Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial

Archives of General Psychiatry

Volumn 58, Issue 6, 2001, Pages 529-534

  De Novaes Soares, Cláudio ^a,c   Almeida, Osvaldo P ^b   Joffe, Hadine ^c   Cohen, Lee S ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; MENOPAUSE; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SIDE EFFECT;

EID: 0035013748     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.58.6.529     Document Type: Article

References (43)

1. Psychiatric morbidity and the menopause: Screening of general population sample
2. Menopause-related affective disorders: A justification for further study
3. The Manitoba Project: A re-examination of the link between menopause and depression
4. Affective symptoms in women attending a menopause clinic
5. Psychologic distress during the menopausal years in women attending a menopause clinic
6. Mental health among perimenopausal women attending a menopause clinic: Possible association with premenstrual syndrome?
7. Depression during the perimenopause
8. The south-east England longitudinal study of the climacteric and postmenopause
9. A longitudinal analysis of the association between menopause and depression: Results from the Massachusetts Women's Health Study
10. Rates and risks of depressive symptoms in a United States urban community
11. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric
12. Is oestrogen therapy effective in the treatment of menopausal depression?
13. Oestrogen therapy and the menopause syndrome
14. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: A placebo-controlled study
15. Transdermal oestrogen for treatment of severe postnatal depression
16. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome
17. Effect of oestradiol on postpartum depression
18. Estrogen replacement in perimenopause-related depression: A preliminary report
19. Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 Study
20. A new depression scale designed to be sensitive to change
21. Vitamin E and climacteric syndrome
22. Montgomery-Åsberg severity gradations
23. A quality of life perspective on who benefits from estradiol replacement therapy
24. Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge?
25. Menopause, mood and hormone replacement therapy: Methodological issues
26. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting
27. The role of oestrogen replacement in the climacteric syndrome
28. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women
29. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol
30. Transdermal delivery of drugs for the treatment of bone diseases
31. New delivery systems for hormone replacement therapy
32. Effects of gonadal steroids in women with a history of postpartum depression
33. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system
34. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women: International Study Group
35. Ovarian steroids and the brain: Implications for cognition and aging
36. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding
37. Modulation of monoamine neurotransmitters by estrogen: Clinical implications
38. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetricgynecologic patients: The PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study
39. A review of unrecognized mental illness in primary care: Prevalence, natural history, and efforts to change the course
40. Depression comes in many disguises to the providers of primary care: Recognition and management
41. Blindness